

Press Release

Three Astellas Research and Production Facilities in Japan Adopt Aqua Premium

- Switching to greenhouse gas emission-free hydroelectric power -

TOKYO, April 6, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that three of its research and production facilities in Japan will be changing their electricity supply plan to the Aqua Premium¹ plan offered by TEPCO Energy Partner, Inc., starting in April 2020. With this change, all electricity consumed by Astellas’ Tsukuba Research Center, Tsukuba Biotechnology Research Center, and Takahagi Chemistry & Technology Development Center will be powered by hydroelectric power, which is free of greenhouse gas (GHG) emissions.

As a company dedicated to improving the health of people around the world, Astellas is conducting its business activities in harmony with the global environment in order to contribute to the development of a sustainable society. Recognizing that addressing climate change mitigation measures is an important corporate focus, Astellas is working proactively to reduce GHG emissions. As part of its efforts, the company has already purchased electricity generated by renewable energy sources at some of its overseas facilities, including wind power and biomass boiler, and the sales force both in and outside of Japan use hybrid vehicles. In 2018, Astellas’ mid-to-long term GHG emission reduction targets, which were revised by backcasting² from the goal that society should aim for by 2050, were recognized as a science-based goal by the Science Based Targets (SBT) initiative³.

The adoption of Aqua Premium is expected to enable the three facilities to reduce the volume of GHG emission in the normal consumption of electricity entirely (approximately 31,000 tons (actual) in 2019) from fiscal year (FY) 2020. Astellas’ target for GHG emissions reduction, which has been recognized by the SBT initiative, is set to reduce its total emissions by 30 % from the base year FY2015 levels by FY2030 (emissions in the base year: 221,000 tons). Astellas believes that adopting Aqua Premium is an important measure that will greatly contribute to meeting the GHG emission reduction target for FY2030.

Astellas will continue to identify and implement measures to help solve global environmental issues, such as climate change, and to make a meaningful contribution

to people all over the world by harmonizing its business activities with the global environment.

- (1) **Aqua Premium:** A pricing plan offered by TEPCO Energy Partner, Inc. that allows customers to buy only hydroelectricity, which does not emit GHG at the time of generation.
- (2) **Backcasting:** A thinking method that starts with defining a desirable future and then working backwards to identify measures and actions.
- (3) **Science Based Targets (SBT) initiative:** Jointly established in 2015 by four organizations: the CDP, the United Nations Global Compact, the World Resources Institute, and the World Wide Fund for Nature, an international initiative to encourage companies and national governments to set GHG reduction targets to achieve the “2 degrees Celsius target,” as agreed under the Paris Agreement of 2015.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Advocacy & Relations
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473